Phaseline

Targets › CEACAM5

CEACAM5 (Cell adhesion molecule CEACAM5): drug programs, companies and trials

25 programs from 22 companies in 41 trials: 32 Phase 1, 6 Phase 3, 3 Phase 2; Oncology, Gastroenterology, Immunology; next expected readout Dec 2026.

Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. (UniProt, P06731)

Open in Phaseline: the race on CEACAM5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GenmabPetosemtamab (MCLA-158)
bispecific antibody targeting EGFR and LGR5
EGFR, CEACAM5, LGR5Phase 3Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid TumorsJan 2028
Post Graduate Institute of Medical Education and Research, ChandigarhCefixime
Bacterial penicillin-binding protein inhibitor
CEACAM5Phase 3Liver Abscess–
SurgimabSGM-101
Fluorochrome-labeled anti-CEA monoclonal antibody
CEACAM5Phase 3Colorectal Neoplasms–
Leiden University Medical CenterSGM-101
CEA-targeted near-infrared fluorophore
CEACAM5Phase 2Pancreas AdenocarcinomaDec 2026
LaNova MedicinesLM-24C5
Anti-CEACAM5 antibody or antibody-drug conjugate
CEACAM5Phase 2Advanced Solid Tumor Cancer; Advanced Solid TumorDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyBecotatug Vedotin
Anti-CEACAM5 antibody-drug conjugate
CEACAM5Phase 2Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal NeoplasmsMar 2027
A2 BiotherapeuticsA2B530
Logic-gated CAR T-cell targeting CEA; selective activation in HLA-A*02 negative cells
CEACAM5Phase 1Solid Tumor, AdultDec 2026
The First People's Hospital of ChangzhouCEA Specific AAV-DC-CTL
CEA-specific cytotoxic T lymphocytes generated from dendritic cells infected with recombin
CEACAM5Phase 1Gastric CancerDec 2026
Changhai HospitalAnti-CEA CAR-T Cells
CAR-T cell therapy targeting carcinoembryonic antigen (CEA)
CEACAM5Phase 1Colorectal CancerDec 2026
Chongqing Precision BiotechCD19 and CD22 targeted prime CAR-T cells
CAR-T cell therapy targeting CEA (CEACAM5)
CD19, CEACAM5Phase 1B-ALL; Advanced Lung Cancer; Systemic Lupus ErythematosusDec 2026
Chongqing Precision BiotechCEA-targeted CAR-T cells
anti-CEA chimeric antigen receptor T cell therapy
CEACAM5Phase 1Gastric Cancer; Colorectal Cancer; Lung Cancer; Peritoneal Metastases From Colorectal Cancer …Dec 2026
Beijing BiotechEB-DUO-CAR-NK-CEA/GCC
Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H
CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15Phase 1Colorectal Cancer; Colorectal Cancer MetastaticMar 2027
Beijing BiotechEB-HC01 dual-target CAR-NK cells
Allogeneic dual-target CAR-NK cells targeting HER2 and CEA/CEACAM5
ERBB2, CEACAM5Phase 1CholangiocarcinomaMar 2027
City of Hope Medical CenterActinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
Anti-CEA antibody-drug conjugate targeting CEA-positive cancer cells, delivering alpha-par
CEACAM5Phase 1Advanced CancerSep 2027
Weijia Fang, MDFAST CEA-targeted CAR-T (PTC13)
anti-CEA CAR-T cell therapy
CEACAM5Phase 1Colorectal CancerDec 2027
Kivu BioscienceKIVU-305
CEACAM5-directed antibody-drug conjugate
CEACAM5Phase 1Solid TumorsDec 2027
Merck KGaAM9140
anti-CEACAM5 antibody-drug conjugate
CEACAM5Phase 1Colorectal Cancer; Solid TumorsDec 2027
Fortvita Biologics (USA)Inc.IBI3020
anti-CEACAM5 monoclonal antibody-drug conjugate
CEACAM5Phase 1Solid TumorsDec 2027
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Ifinatamab Deruxtecan (I-DXd, DS-7300a, MK-2400)
Anti-CEACAM5 antibody-drug conjugate
CEACAM5Phase 1Small-Cell Lung CancerJan 2028
Adlai Nortye BiopharmaAN4035
CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload
CEACAM5, KRAS, NRAS, HRASPhase 1Solid Tumor (Phase I)Dec 2028
PfizerPF-08046050
CEACAM5-targeting antibody-drug conjugate
CEACAM5Phase 1Colorectal NeoplasmsSep 2029
Bristol-Myers SquibbBMS-986490
anti-CEACAM5 antibody
CEACAM5Phase 1Advanced Solid TumorsDec 2029
RocheSPLIT Abs (RO7782304, RO7782306)
CEA-targeting pretargeting antibody for radioimmunotherapy
CEACAM5Phase 1Metastatic Colorectal CancerFeb 2034
Harbour BioMed (Guangzhou)HBM4003 (Porustobart)
Anti-CEACAM5 antibody
CEACAM5Phase 1Solid Tumors–
Merck KGaAM9140
anti-CEACAM5 antibody-drug conjugate
CEACAM5Phase 1Solid Tumors–

Conditions

Colorectal Cancer (6) Solid Tumors (5) Advanced Lung Cancer (4) Gastric Cancer (2) Head and Neck Squamous Cell Carcinoma (2) Colorectal Neoplasms (2) Lung Cancer (1) Peritoneal Metastases From Colorectal Cancer (1) NSCLC (Advanced Non-small Cell Lung Cancer) (1) Solid Tumor, Adult (1) Metastatic Colorectal Cancer (1) Advanced Solid Tumors (1)

Modalities

small molecule (7), antibody (7), other (4), mixed (4), protein or peptide (2)

Companies

Chongqing Precision Biotech (2) Beijing Biotech (2) Merck KGaA (2) A2 Biotherapeutics (1) Roche (1) Bristol-Myers Squibb (1) Post Graduate Institute of Medical Education and Research, Chandigarh (1) LaNova Medicines (1) Weijia Fang, MD (1) Genmab (1) Changhai Hospital (1) Harbour BioMed (Guangzhou) (1) Kivu Bioscience (1) Leiden University Medical Center (1) Fortvita Biologics (USA)Inc. (1) Pfizer (1) Surgimab (1) Adlai Nortye Biopharma (1) City of Hope Medical Center (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)

Related targets

ERBB2 (2) GUCY2C (1) CEA (1) HER2 (1) IL15 (1) EGFR (1) LGR5 (1) CD19 (1) KRAS (1) NRAS (1) HRAS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.